STEMIN Polypeptide Induces Cardiomyocyte Regeneration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for deriving cardiomyocytes from stem cells, such as embryonic stem cells and induced pluripotent stem cells, face challenges including prolonged culture times, absence of T-tubules, impaired Ca2+ handling, and ethical issues, leading to ineffective cardiac repair post-myocardial infarction.
Innovation Solution
The use of a STEMIN polypeptide, delivered via a heterologous cell permeability peptide or expression cassette, including viral or non-viral vectors, to induce cell de-differentiation of cardiac fibroblasts into cardiomyocyte-like cells, potentially combined with secondary anti-hypertrophic therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If stem cell methods are used to derive cardiomyocytes, then cardiac repair is possible, but culture time is prolonged (60 days or greater) and functional maturity is impaired
Solution Approach 1:
The patent applies preliminary action by pre-differentiating cardiac progenitor cells into cardiomyocyte-like cells before transplantation. This allows the cells to undergo initial maturation and functional development in vitro, reducing the subsequent in vivo culture time and accelerating the overall cardiac repair process while maintaining cell functionality.
Solution Approach 2:
The patent employs parameter changes by modifying culture conditions including serum concentration, growth factors, and oxygen levels to accelerate cardiomyocyte differentiation and maturation. These parameter optimizations reduce culture time from 60+ days to shorter periods while improving cell functional maturity and reducing arrhythmias.
2Reliability
If embryonic stem cells are used, then cardiomyocytes can be derived, but ethical issues and teratoma formation risk arise
Solution Approach 1:
The patent extracts the essential function of stem cell-derived cardiomyocytes by using induced pluripotent stem cells (iPSCs) instead of embryonic stem cells. This substitution eliminates ethical concerns associated with embryo destruction and reduces teratoma formation risk through patient-specific autologous cell therapy, while maintaining the ability to derive functional cardiomyocytes.
Solution Approach 2:
The patent employs patient-specific iPSC-derived cardiomyocytes as a disposable, autologous cell therapy approach. Each patient receives their own genetically matched cells, eliminating the need for long-term immunosuppression and reducing the risk of teratoma formation compared to prolonged embryonic stem cell cultures.
3Quantity of substance
If prolonged culture is used to mature cardiomyocytes, then cell quantity increases, but functional properties deteriorate (absent T-tubules, poor Ca2+ handling)
Solution Approach 1:
The patent applies periodic action by using cyclic serum starvation and refeeding protocols, along with periodic exposure to differentiation-inducing factors. This rhythmic stimulation promotes synchronized cardiomyocyte maturation, T-tubule formation, and Ca2+ handling improvement without requiring excessively prolonged culture periods, thereby maintaining functional precision while achieving sufficient cell numbers.
Solution Approach 2:
The patent employs dynamic culture conditions that change over time, including progressive reduction of growth factors, gradual serum concentration adjustments, and timed addition of maturation promoters. This dynamic approach accelerates functional maturation of cardiomyocytes, ensuring proper T-tubule assembly and Ca2+ handling properties develop during the culture period.
Data Source
AI summary
Loss of cardiomyocytes underlies most causes of heart failure, and normal repair processes are inadequate to deal with extensive myocardial damage. The inventors have identified mutations of the N-terminus of serum respose factor (SRF)'s MADS box, termed STEMINs, that block cardiac differentiation, but also powerfully activate the stem cell marker genes Nanog and Octomer 4, as well as cyclins, which promotes adult myocyte replication. SRF Stemin mutations are not cardiac-specific, and also propel mammalian fibroblasts into a proliferative state. Thus, STEMINs may be useful for regeneration of all tissue and organ types, by activating partial pluripotency programs and enhacing repair by increased cell replication. Following withdrawal of STEMINs, the cells then return to normal cell identity.